EDIT

$0.00

(

0.00%

)
Quote details

stock

Editas Medicine Inc

NASDAQ | EDIT

2.96

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Aug 14, 2025)

$277M

MARKET CAP

-

P/E Ratio

-2.84

EPS

$4.2

52 Week High

$0.91

52 Week Low

LIFE SCIENCES

Sector

EDIT Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

EDIT Technicals

Tags:

EDIT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $27M
Total Revenue $32M
Cost Of Revenue $5.8M
Costof Goods And Services Sold $5.8M
Operating Income -$239M
Selling General And Administrative $72M
Research And Development $199M
Operating Expenses $265M
Investment Income Net -
Net Interest Income $14M
Interest Income $14M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5.8M
Income Before Tax -$237M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$237M
Comprehensive Income Net Of Tax -
Ebit -$239M
Ebitda -$233M
Net Income -$237M

Revenue & Profitability

Earnings Performance

EDIT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $342M
Total Current Assets $289M
Cash And Cash Equivalents At Carrying Value $132M
Cash And Short Term Investments $132M
Inventory -
Current Net Receivables $16M
Total Non Current Assets $52M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $138M
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $207M
Total Current Liabilities $77M
Current Accounts Payable $5.5M
Deferred Revenue -
Current Debt -
Short Term Debt $29M
Total Non Current Liabilities $130M
Capital Lease Obligations $35M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $35M
Other Current Liabilities $36M
Other Non Current Liabilities $3.1M
Total Shareholder Equity $134M
Treasury Stock -
Retained Earnings -$1.5B
Common Stock $8K
Common Stock Shares Outstanding $82M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$210M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $5.8M
Capital Expenditures $8.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $162M
Cashflow From Financing $56M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$237M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $27M
Total Revenue $32M
Cost Of Revenue $5.8M
Costof Goods And Services Sold $5.8M
Operating Income -$239M
Selling General And Administrative $72M
Research And Development $199M
Operating Expenses $265M
Investment Income Net -
Net Interest Income $14M
Interest Income $14M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5.8M
Income Before Tax -$237M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$237M
Comprehensive Income Net Of Tax -
Ebit -$239M
Ebitda -$233M
Net Income -$237M

EDIT News

EDIT Profile

Editas Medicine Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Discover more tools and features to empower your trading
Explore Features

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.